BioSpace News Archive

Vaccitech plc will present positive final data from the HBV002 clinical trial at the European Association for the Study of the Liver (EASL) Congress 2023.

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for BLINCYTO.

Mediso has announced the Food and Drug Administration (FDA) clearance of the InterView™ FUSION and InterView™ XP multimodality (PET/SPECT/MRI/CT) image processing and reporting software which is specifically adapted for nuclear medicine and molecular imaging workflows.

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd., a Japan-based global specialty pharmaceutical company, announced that Gunnar Kaufmann, Ph.D., has been named Chief Research Officer.

Bionano Genomics, Inc. (BNGO), today announced that the company will participate at the Healthcare Virtual Conference, presented by Maxim Group LLC and hosted by M-Vest. Erik Holmlin, Ph.D., Bionano’s president and chief executive officer, is scheduled to present a company overview and fire-side chat discussion hosted by Michael Okunewitch, Senior Research Analyst at Maxim Group on Wednesday, June 21, 2023 at 12:30 pm ET.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that clinical study results relating to LX9211, its investigational drug for the treatment of diabetic peripheral neuropathic pain, and INPEFA™ (sotagliflozin), its recently approved drug for heart failure, will be featured as Oral Presentations focused on treatment of complications of diabetes during the American Diabetes Association’s 83rd Scientific Sessions, June 23-26, 2023.

Clario and the Tufts Center for the Study of Drug Development (CSDD) will present the results of new research highlighting critical levels of under-representation by race and ethnicity in pivotal trials supporting drugs and biologics approved between 2007 and 2021.

Alderya Therapeutics (Nasdaq: ALDX) (Aldeyra) today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the 505(b)(2) New Drug Application (NDA) of ADX-2191 (methotrexate for injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma (PVRL).

Quest Diagnostics Incorporated (NYSE: DGX) announced that it will report second quarter 2023 financial results on Wednesday, July 26, 2023, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day.

Bayer, one of the country’s leading life-sciences companies, announced its new Senior Bayer Representative and President of Bayer U.S. This press release features multimedia.